Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | INSR | P06213 | 6/20 | 0.39 |
| ▸ | ALK | Q9UM73 | 5/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SMO | Q99835 | 6/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.33 |
| ▸ | PLAU | P00749 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | THPO | P40225 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16243311 | 0.83 | CDK2 (0.37) | INSRALKSMOHCRTR2CYP3A4 | |
| SCHEMBL2061553 | 0.74 | ALK (0.52) | INSRALKSMOJAK2JAK1 | |
| SCHEMBL16965908 | 0.74 | ALK (0.52) | INSRALKSMOJAK2JAK1 | |
| SCHEMBL2061087 | 0.74 | ALK (0.52) | INSRALKSMOJAK2JAK1 | |
| SCHEMBL2061744 | 0.74 | ALK (0.52) | INSRALKSMOJAK2JAK1 | |
| SCHEMBL2060480 | 0.74 | ALK (0.52) | INSRALKSMOJAK2JAK1 | |
| SCHEMBL2060387 | 0.71 | ALK (0.49) | INSRALKSMOJAK2JAK1 | |
| SCHEMBL2060390 | 0.71 | ALK (0.49) | INSRALKSMOJAK2JAK1 | |
| SCHEMBL2060389 | 0.71 | ALK (0.49) | INSRALKSMOJAK2JAK1 | |
| SCHEMBL4836163 | 0.68 | POLB (0.41) | SMN1; SMN2ALDH1A1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9238656-B2 | Imidazo[4,5-b]pyridine derivatives as ALK and JAK modulators for the treatment of proliferative disorders | CEPHALON, INC. (US) | 2016-01-19 | — | — | US | disclosed |
| EP-2809671-B1 | IMIDAZO [4, 5 - B]PYRIDINE DERIVATIVES AS ALK AND JAK MODULATORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | CEPHALON INC (US) | 2016-01-13 | — | — | EP | disclosed |
| US-20140350011-A1 | Imidazo[4,5-b]pyridine Derivatives as ALK and JAK Modulators for the Treatment of Proliferative Disorders | CEPHALON, INC. | 2014-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140350011-A1 | Imidazo[4,5-b]pyridine Derivatives as ALK and JAK Modulators for the Treatment of Proliferative Disorders | JAK1, ALK, JAK2 | INSR 752/4885ALK 2/4885SMN1; SMN2 4305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.